ClinicalTrials.gg

Program

KP-001

A development code.

Its studies are mostly in Lymphatic Abnormalities, led by Kaken Pharmaceutical.

Furthest: phase 3, since Nov 19, 20253 company-led studies, 1 open or runningNext primary completion: Feb 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kaken Pharmaceutical31 open or runningphase 3since Nov 19, 2025Sep 12, 2024Feb 2028phase 3 · NCT07285005

Also a collaborator on its studies: parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 12, 2024First studies: 2 phase 1 studiesFirst studyNCT06619054, NCT06649942
  2. Nov 19, 2025Phase 3 study in Lymphatic AbnormalitiesPhase 3 reachedNCT07285005 · 150 planned · United States, South Korea, Taiwan

Ahead

  1. Feb 2028Primary completion: phase 3 study in Lymphatic AbnormalitiesNCT07285005

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07285005Lymphatic Abnormalities · United States, South Korea, Taiwan3RecruitingFeb 2028150
NCT06649942Healthy Volunteers - Male and Female · United States1CompletedMar 24, 202540
NCT06619054Healthy Adults · United States1CompletedMay 16, 202524

How it is read

Names in the registry

  • “KP-001”, 4 entries

Codes read as this program: KP001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.